Neuromuscular Blockade in Patients With Severe Renal Impairment
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Neuromuscular Blockade
- Renal Impairment
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: single site, randomized, controlledMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Masking Description: double blindedPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 80 years
- Gender
- Both males and females
Description
This will be a prospective, randomized, double-blinded study of surgical patients with severe renal impairment that seeks to address the following: Specific Aim: To determine whether rocuronium-induced moderate neuromuscular blockade and reversal with sugammadex achieves recovery of neuromuscular fu...
This will be a prospective, randomized, double-blinded study of surgical patients with severe renal impairment that seeks to address the following: Specific Aim: To determine whether rocuronium-induced moderate neuromuscular blockade and reversal with sugammadex achieves recovery of neuromuscular function (TOF ? 0.9) faster than reversal of cisatracurium-induced moderate neuromuscular blockade and reversal with neostigmine in patients with severe renal impairment. Primary Hypothesis: Patients with severe renal impairment who are reversed with sugammadex after rocuronium will achieve a TOF ?0.9 within a time frame that is one-third of the time it takes for reversal with neostigmine after cisatracurium.
Tracking Information
- NCT #
- NCT03904550
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Tiffany Moon, MD University of Texas Southwestern Medical Center
Get Well Soon